^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | amcenestrant (SAR439859) (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
Excerpt:
...- Estrogen receptor(ER) positive status....
Trial ID:
Source:
Title:
739-Preclinical and clinical activity of SAR439859, Amcenestrant, a next generation SERD
Published date:
03/10/2021
Excerpt:
In the clinical setting, SAR439859 also demonstrated a high level of target engagement, ER degradation and inhibition of ER signaling as well as encouraging anti-tumor activity in heavily pretreated patients with advanced or metastatic ER-positive breast cancer.
Source:
Title:
Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER+ endocrine-resistant breast cancer xenograft models
Published date:
10/09/2021
Excerpt:
Here, we report that in preclinical models, amcenestrant achieved significant anti-tumor efficacy/regression as a monotherapy and strong synergistic activity when administered together with the CDK4/6 inhibitor, palbociclib, in subcutaneously xenografted endocrine resistant ER+ BC mouse models
Secondary therapy:
CDK4 inhibitor + CDK6 inhibitor
Source:
Title:
Abstract 3452: Pre-clinical development of next generation selective estrogen receptor degrader - SAR439859
Published date:
08/15/2020
Excerpt:
SAR439859 demonstrates broad anti-tumor activity in ER+ breast cancer cell line/PDX models. Anti-tumor efficacy correlates with PK exposure/PD modulation in target tissue.
DOI:
10.1158/1538-7445.AM2020-3452
